drugset / Trial / NCT01140412
Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
This is will be an open-label, fixed-sequence, multiple dose crossover study in 2 cohorts of 14 healthy male and/or female subjects, to estimate the effect of maraviroc on the pharmacokinetics of amprenavir and ritonavir and fosamprenavir/ritonavir on the pharmacokinetics of maraviroc.
Timeline
- Start
- 2010-07
- Primary completion
- 2010-10
- Completion
- 2010-10
Outcome
Outcome not reported
Stopped: “The trial prematurely terminated on November 1, 2010, due to healthy volunteer participants experiencing non-serious fosamprenavir-related skin rash.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fosamprenavir | Small molecule | 700 mg | — |
| Subject | Fosamprenavir | Small molecule | 1400 mg | — |
| Subject | Maraviroc | Other / unclassified | 300 mg | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |
Indications
No indication recorded.